
Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
How to Cite
OrthoEvidence. Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy. ACE Report. 2013;2(3):12. Available from: https://myorthoevidene.com/AceReport/Report/4343
Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma
Cancer. 2012 Dec 1;118(23):5888-93Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...
To view the full report, start your 30-day free trial today
No credit card required
JOIN LOGIN Forgot Password?Not sure if you want to join OrthoEvidence?
Access this report without an Account.Success, an email containing a link to access this report has been sent to your inbox.
Explore some of our unlocked reports below!

Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE